Multiple Myeloma Management in 2021

EP. 1: Overview of Smoldering Multiple Myeloma

January 27th 2021

EP. 2: Role of Therapeutic Intervention in SMM

January 27th 2021

EP. 3: Approaching Early Treatment of High-Risk SMM

February 3rd 2021

EP. 4: Individualized Induction Therapy for NDMM

February 3rd 2021

EP. 5: ASH Updates on Transplant in NDMM

February 10th 2021

EP. 6: Future of MRD Assessment in NDMM

February 10th 2021

EP. 7: Approaching Treatment of RRMM

February 18th 2021

EP. 8: Role of IMiD-based Strategies for RRMM

February 18th 2021

EP. 9: Using PI-based Combinations in RRMM

February 25th 2021

Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.

EP. 10: Emerging Novel Agents in RRMM

February 25th 2021

Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM. 

EP. 11: Targeting BCMA and CAR T Therapy in RRMM

March 4th 2021

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 

EP. 12: Investigational BCMA Targets in RRMM

March 4th 2021

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

EP. 13: Non-BCMA Specific Targets in RRMM

March 11th 2021

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

EP. 14: Sequencing BCMA-Targeted Agents in RRMM

March 11th 2021

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

EP. 15: ASH Takeaways and Future Directions for Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management.